• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

黑非洲男性的前列腺恶性肿瘤和良性前列腺增生微环境：CD8+ T 淋巴细胞、NK 细胞浸润有限，CD73+基质细胞频率高。

Prostate malignant tumor and benign prostatic hyperplasia microenvironments in black African men: Limited infiltration of CD8+ T lymphocytes, NK-cells, and high frequency of CD73+ stromal cells.

机构信息

Service d'Immunologie, Département des Sciences Fondamentales, Faculté de Médecine, Université des Sciences de la Santé, Libreville, Gabon.

Service d'Immunologie, Département des Sciences Biologiques et Pharmaceutiques Appliquées, Faculté de Médecine, de Pharmacie et d'Odontostomatologie, Université Cheikh Anta Diop, Dakar, Senegal.

出版信息

Cancer Rep (Hoboken). 2023 Sep;6 Suppl 1(Suppl 1):e1817. doi: 10.1002/cnr2.1817. Epub 2023 Apr 24.

DOI:10.1002/cnr2.1817
PMID:37092584
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10440842/
Abstract

BACKGROUND

Anti-cancerous immunology has yet to be investigated in the African black population, despite being the dawn of precision medicine.

AIM

Here we investigated the tumor microenvironment of prostate cancer and benign prostatic hyperplasia (BPH) in black Africans.

METHODS

Through immunohistochemistry analysis of prostate cancer and BPH patients' biopsies, we investigated the expression and distribution of CD73, CCD8 T-lymphocytes, and natural killer cells. In addition, we looked at tumor-infiltrating features CD8 T-lymphocytes and natural killer cells.

RESULTS

We show for the first time in black Africans a high expression of CD73 in epithelial-stromal cells and virtually no infiltration of CD8 T lymphocytes and natural killer cells in the tumoral area. In addition, CD73 was seven (7) times more likely to be expressed in prostate cancer stromal tissues than in benign prostatic hyperplasia tissues (odds ratio = 7.2; χ  = 21; p < .0001). In addition, PSA concentration was significantly higher in prostate cancer patients than in BPH patients (p < .001). Also, the PSA-based ROC. analysis showed an area under the curve of 0.87 (p < .0001).

CONCLUSION

CD73 expression is more likely expressed in prostate cancer stromal tissues than in benign prostatic hyperplasia tissues. The features of prostate cancer in Black Africans suggest CD73 expression as a possible target for immunotherapy in this population.

摘要

背景

尽管精准医学已经崭露头角，但抗癌免疫学在非洲黑人人群中尚未得到研究。

目的

本研究旨在探讨非洲黑人前列腺癌和良性前列腺增生（BPH）的肿瘤微环境。

方法

通过对前列腺癌和 BPH 患者活检组织的免疫组织化学分析，我们研究了 CD73、CCD8 T 淋巴细胞和自然杀伤细胞的表达和分布。此外，我们还观察了肿瘤浸润的 CD8 T 淋巴细胞和自然杀伤细胞特征。

结果

我们首次在非洲黑人中显示，上皮-间质细胞中 CD73 的表达较高，而肿瘤区域几乎没有 CD8 T 淋巴细胞和自然杀伤细胞浸润。此外，CD73 在前列腺癌基质组织中的表达是良性前列腺增生组织的七倍（比值比=7.2；χ²=21；p<0.0001）。此外，前列腺癌患者的 PSA 浓度显著高于 BPH 患者（p<0.001）。另外，PSA 为基础的 ROC 分析显示曲线下面积为 0.87（p<0.0001）。

结论

CD73 的表达在前列腺癌基质组织中比良性前列腺增生组织中更为常见。非洲黑人前列腺癌的特征表明，CD73 表达可能是该人群免疫治疗的一个潜在靶点。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/279f/10440842/1e18d6cfa5d6/CNR2-6-e1817-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/279f/10440842/30056a202945/CNR2-6-e1817-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/279f/10440842/9b37687ebe0b/CNR2-6-e1817-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/279f/10440842/dd5967734b20/CNR2-6-e1817-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/279f/10440842/effcb059f9d1/CNR2-6-e1817-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/279f/10440842/a1a5c48728ab/CNR2-6-e1817-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/279f/10440842/f15bd0d05d7b/CNR2-6-e1817-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/279f/10440842/1e18d6cfa5d6/CNR2-6-e1817-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/279f/10440842/30056a202945/CNR2-6-e1817-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/279f/10440842/9b37687ebe0b/CNR2-6-e1817-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/279f/10440842/dd5967734b20/CNR2-6-e1817-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/279f/10440842/effcb059f9d1/CNR2-6-e1817-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/279f/10440842/a1a5c48728ab/CNR2-6-e1817-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/279f/10440842/f15bd0d05d7b/CNR2-6-e1817-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/279f/10440842/1e18d6cfa5d6/CNR2-6-e1817-g001.jpg

相似文献

1
Prostate malignant tumor and benign prostatic hyperplasia microenvironments in black African men: Limited infiltration of CD8+ T lymphocytes, NK-cells, and high frequency of CD73+ stromal cells.黑非洲男性的前列腺恶性肿瘤和良性前列腺增生微环境：CD8+ T 淋巴细胞、NK 细胞浸润有限，CD73+基质细胞频率高。
Cancer Rep (Hoboken). 2023 Sep;6 Suppl 1(Suppl 1):e1817. doi: 10.1002/cnr2.1817. Epub 2023 Apr 24.
2
Expression analysis of thrombospondin 2 in prostate cancer and benign prostatic hyperplasia.血栓反应蛋白 2 在前列腺癌和良性前列腺增生中的表达分析。
Exp Mol Pathol. 2013 Jun;94(3):438-44. doi: 10.1016/j.yexmp.2013.02.002. Epub 2013 Mar 5.
3
Comparative study of frequency of different lymphocytes subpopulation in peripheral blood of patients with prostate cancer and benign prostatic hyperplasia.前列腺癌与良性前列腺增生患者外周血不同淋巴细胞亚群频率的比较研究。
Wien Klin Wochenschr. 2011 Dec;123(23-24):718-25. doi: 10.1007/s00508-011-0096-7. Epub 2011 Nov 23.
4
Dominance of CD4+ lymphocytic infiltrates with disturbed effector cell characteristics in the tumor microenvironment of prostate carcinoma.前列腺癌肿瘤微环境中具有效应细胞特征紊乱的CD4 +淋巴细胞浸润占主导。
Prostate. 2008 Jan 1;68(1):1-10. doi: 10.1002/pros.20661.
5
Sex steroid receptor expression and localization in benign prostatic hyperplasia varies with tissue compartment.在良性前列腺增生中，性类固醇受体的表达和定位随组织隔室而变化。
Differentiation. 2013 Apr-Jun;85(4-5):140-9. doi: 10.1016/j.diff.2013.02.006. Epub 2013 Jun 20.
6
Stromal response to prostate cancer: nanotechnology-based detection of thioredoxin-interacting protein partners distinguishes prostate cancer associated stroma from that of benign prostatic hyperplasia.前列腺癌的基质反应：基于纳米技术的硫氧还蛋白相互作用蛋白伴侣检测可区分前列腺癌相关基质与良性前列腺增生的基质。
PLoS One. 2013 Jun 6;8(6):e60562. doi: 10.1371/journal.pone.0060562. Print 2013.
7
Activation of cGMP/PKG/p65 signaling associated with PDE5-Is downregulates CCL5 secretion by CD8 T cells in benign prostatic hyperplasia.cGMP/PKG/p65 信号的激活与 PDE5-Is 下调良性前列腺增生中 CD8+T 细胞分泌的 CCL5。
Prostate. 2019 Jun;79(8):909-919. doi: 10.1002/pros.23801. Epub 2019 Apr 8.
8
Phenotypic characterization of infiltrating leukocytes in benign prostatic hyperplasia.良性前列腺增生中浸润性白细胞的表型特征
Lab Invest. 1992 Jan;66(1):96-107.
9
Correlation of cell proliferation marker (TPS), natural killer (NK) activity and tumor load serotest (PSA) in untreated and treated prostatic tumors.未治疗和已治疗前列腺肿瘤中细胞增殖标志物（TPS）、自然杀伤（NK）活性与肿瘤负荷血清检测指标（PSA）的相关性
Anticancer Res. 1993 Jan-Feb;13(1):215-8.
10
Immunohistochemical finding of alpha-1-antichymotrypsin in tissues of benign prostatic hyperplasia and prostate cancer.良性前列腺增生和前列腺癌组织中α-1-抗糜蛋白酶的免疫组化结果
Int J Urol. 1999 Dec;6(12):600-6. doi: 10.1046/j.1442-2042.1999.00118.x.

引用本文的文献

1
Bolstering CD8 T Cells' Antitumor Immunity: A Promising Strategy to Improve the Response to Advanced Prostate Cancer Treatment.增强CD8 T细胞的抗肿瘤免疫力：一种改善晚期前列腺癌治疗反应的有前景的策略。
Biology (Basel). 2025 May 14;14(5):544. doi: 10.3390/biology14050544.
2
Bridging racial and ethnic disparities in cancer research.弥合癌症研究中的种族和族裔差异。
Cancer Rep (Hoboken). 2023 Sep;6 Suppl 1(Suppl 1):e1871. doi: 10.1002/cnr2.1871. Epub 2023 Aug 1.

本文引用的文献

1
Lymphocytes from B-acute lymphoblastic leukemia patients present differential regulation of the adenosinergic axis depending on risk stratification.B 急性淋巴细胞白血病患者的淋巴细胞根据风险分层呈现出腺苷能轴的差异调节。
Discov Oncol. 2022 Dec 30;13(1):143. doi: 10.1007/s12672-022-00602-1.
2
Health inequity drives disease biology to create disparities in prostate cancer outcomes.健康不平等导致疾病生物学产生前列腺癌结果的差异。
J Clin Invest. 2022 Feb 1;132(3). doi: 10.1172/JCI155031.
3
Racial and Ethnic Disparities in Prostate Cancer Outcomes in the Veterans Affairs Health Care System.
退伍军人事务部医疗保健系统中前列腺癌结局的种族和民族差异。
JAMA Netw Open. 2022 Jan 4;5(1):e2144027. doi: 10.1001/jamanetworkopen.2021.44027.
4
Regulation of immune responses through CD39 and CD73 in cancer: Novel checkpoints.癌症中通过CD39和CD73对免疫反应的调节：新型检查点。
Life Sci. 2021 Oct 1;282:119826. doi: 10.1016/j.lfs.2021.119826. Epub 2021 Jul 12.
5
Differential diagnosis of uncommon prostate diseases: combining mpMRI and clinical information.罕见前列腺疾病的鉴别诊断：mpMRI与临床信息相结合
Insights Imaging. 2021 Jun 16;12(1):79. doi: 10.1186/s13244-021-01024-3.
6
Cancer in Africa: The Untold Story.非洲的癌症：不为人知的故事。
Front Oncol. 2021 Apr 15;11:650117. doi: 10.3389/fonc.2021.650117. eCollection 2021.
7
Androgen Receptor-Dependent Mechanisms Mediating Drug Resistance in Prostate Cancer.雄激素受体依赖性机制介导前列腺癌的耐药性。
Cancers (Basel). 2021 Mar 26;13(7):1534. doi: 10.3390/cancers13071534.
8
Impact of Lifestyle Behaviors on Cancer Risk and Prevention.生活方式行为对癌症风险及预防的影响。
J Lifestyle Med. 2021 Jan 31;11(1):1-7. doi: 10.15280/jlm.2021.11.1.1.
9
Blocking CD73 Can Shrink Pancreatic Tumors.阻断CD73可使胰腺肿瘤缩小。
Cancer Discov. 2021 May;11(5):OF4. doi: 10.1158/2159-8290.CD-NB2021-0313. Epub 2021 Feb 12.
10
Plasma cells are enriched in localized prostate cancer in Black men and are associated with improved outcomes.黑人男性局部前列腺癌中富含浆细胞，且与改善预后相关。
Nat Commun. 2021 Feb 10;12(1):935. doi: 10.1038/s41467-021-21245-w.